Brittany Bychkovsky, MD MSc

Brittany Bychkovsky, MD MSc

Instructor of Medicine / Physician
Harvard Medical School / Dana-Farber Cancer Institute

Dr. Brittany Bychkovsky is a medical oncologist at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (DFCI/BWH), and is faculty at Harvard Medical School. She graduated from Harvard Medical School in 2008 and completed her residency training at Massachusetts General Hospital (MGH, 2011) and her fellowship at Beth Israel Deaconess Medical Center (2015). In her clinical practice, she provides care that spans the cancer continuum from prevention to end-of-life. At DFCI/BWH, she focuses on cancer genetics and prevention for women who are high risk for breast cancer. Her research focuses on clinical care, quality improvement, and access to care. She is passionate about her academic work and hopes that her efforts will improve cancer care both locally in her community and on a global scale.

Dr. Bychkovsky is actively involved in global oncology efforts and received mentorship from Dr. Paul Goss during her residency and fellowship. During her medical training, she completed clinical rotations in Guatemala, Chile, and Brazil. In 2014, she rotated at Pontifical Catholic University of Rio Grande do Sul in Porto Alegre, Brazil, and this experience prompted her to review breast cancer care in Brazil and this review was published in Lancet Oncology. Dr. Bychkovsky has subsequently participated in commissioned reviews of cancer control in Latin America, China, India, and Russia, also published by Lancet Oncology. The goal of these works was to highlight global cancer disparities and to advocate for better cancer prevention, screening, and treatment in low- and middle-income countries (LMICs). Since 2015, Dr. Bychkovsky has been an expert panelist with the Global Cancer Institute and participated in the breast oncology tumor boards. She hopes that these efforts improve care for patients with breast cancer around the world.

Interest/specialization: Breast cancer genetics, High-risk of breast cancer, Treatment, and management of BRCA-associated breast cancer, Cancer control in LMICs